Enanta Pharma (ENTA) Tops Q3 EPS by 39c, beats revenue

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($1.86), $0.39 better than the analyst estimate of ($2.25). Revenue for the quarter came in at $18.89 million versus the consensus estimate of $18.19 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
• Deutsche Bank Upgrades PennyMac Mortgage Investment Trust (PMT) to Buy